Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Neoadjuvant Degarelix on MRI-guided Transurethral Ultrasound Ablation (TULSA) in Patients With Intermediate-risk Prostate Cancer: A Pilot Study

NCT05917860 is registered in ClinicalTrials.gov with Turku University Hospital as lead sponsor.

NCT NCT05917860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05917860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Neoadjuvant Degarelix on MRI-guided Transurethral Ultrasound Ablation (TULSA) in Patients With Intermediate-risk Prostate Cancer: A Pilot Study
Lead sponsor
Turku University Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 18, 2023
Completion date
January 31, 2030
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-naive prostate cancer, intermediate risk prostate cancer, localized prostate carcinoma, prostate cancer